Project title: DEVELOPMENT OF IGF1R INHIBITORS AS ANTI-CANCER AGENTS

Company name : NOVOTYR THERAPEUTICS LTD.

LTD.

TECHNOLOGICAL FIELD
Biotechnology, Health Care,
Pharmaceutical

KEY WORDS
Tyrosine Kinase Inhibitor, IGF1R,
Apoptosis, Small Molecule Drug

PROJECT SUMMARY
NovoTyr develops novel inhibitors of insulin-like growth factor
receptor (IGF1R), as drugs for the treatment of cancer and other
inflammatory disorders.

TECHNOLOGY
ADVANTAGES:
* Unique approach & long-lasting effects: The unique developed
IGF1R inhibitors not only inhibit the tyrosine kinase activity of
IGF1R, but also induce a long-lasting elimination of the protein
levels of IGF1R direct substrate IRS1. This gives a clear
advantage to NovoTyr's lead candidate over competitor solutions.
IRS1 elimination blocks IGF1R signaling for a very long period,
leading to apoptosis of the cancer cell (programmed cell death).
* The inhibitors are proprietary novel small molecules.

TARGET ADVANTAGES:
* Specificity: In contrast to normal cells the viability of
various cancer cells is dependent on IGF1R activity. Therefore,
IGF1R inhibitors selectively affect tumor cells with little or no
toxic effects on normal cells.
* Target is expressed throughout the disease progression: IGF1R
inhibitors are developed to treat primary tumors as well as
advanced metastatic cancers.
* Synergy with other treatment modalities: IGF1R inhibitors will
be used as a mono-therapy or in combination with conventional
chemotherapy or radiation. IGF1R activity is enhanced in
chemotherapy and irradiation refractory cancer cells, and its
inhibition will sensitize these cells to apoptosis (programmed
cell death).

THE MARKET - According to a recent report published by BCC
research, the worldwide market for clinical use of kinase
inhibitors reached $4.63 billion in 2005 and will rise at an
average annual growth rate (AAGR) of 20.6% to $11.8 billion by
2010. The major disease application for kinase inhibitors is
oncology that comprises nearly 90% of kinase inhibitor sales in
2005 and is expected to grow at an AAGR of 21.5%.

ENTREPRENEURS
Prof. Alexander Levitzki -
Founder & Director
Dr. Hadas Reuveni -
CEO & Inventor

PROJECT STATUS
NovoTyr was founded on March 2005. During the first year of
activity NovoTyr has developed a novel and potent inhibitor of
IGF1R, designated NT52, with several unique features: It induces
a specific reduction in the levels of IGF1R-direct substrate IRS1
in cancer cells. This effect is long-lasting and correlates with
high anti-cancer activity in-vitro and in-vivo. NT52 leads to the
inhibition of the central anti-apoptotic pathway in cancer cells,
the activation of PKB, and to a subsequent apoptosis of these
cells. In a successful process of lead-optimization, NovoTyr
designed and characterized improved 2nd generation proprietary
leads, covered by a recently filed patent application. In-vivo
experiments in human tumor-transplanted nude mice, evaluating the
efficacy of NT52 and the improved derivatives, show significant
and pronounced inhibitory effects in prostate cancer, ovarian
cancer and melanoma models. NovoTyr will initiate preclinical
development of the selected lead compound at 2009.

In 2008, Teva Pharmaceutical Industries Ltd. signed an investment
agreement with NovoTyr for the codevelopment of novel IGF1R
inhibitors. At the end of phase II Teva will have the option for
a worldwide and exclusive license for further development and
marketing of the drug

COOPERATION REQUIRED
The Company is seeking a strategic partner for joined development
of selected leads.
----------------------------------------
TEL: 972-54-2666041, E-MAIL: hadas.reuveni@gmail.com

Request for more information, about this project.

Note - you have to be registered in this server to request information. If you haven't done so yet, please:
Register in this server and your requests will be forwarded to the developer, who will contact you directly

List of projects that you already requested more information about